Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc

“Topological Significance” Analysis of Gene Expression and Proteomic Profiles from Prostate Cancer Cells Reveals Key Mechanisms of Androgen Response

(2010) Adaikkalam Vellaichamy et al.   PLoS One

A Randomized Phase 1 Study of Testosterone Replacement for Patients with Low-Risk Castration-Resistant Prostate Cancer

(2009) Russell Szmulewitz et al.   EUROPEAN UROLOGY

Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer

(2009) N. L. Keating et al.   JNCI-Journal of the National Cancer Institute

Suppression of androgen receptor signaling and prostate specific antigen expression by (−)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells

(2008) Chih-Pin Chuu et al.   CANCER LETTERS

Intermittent androgen blockade should be regarded as standard therapy in prostate cancer

(2008) Bostjan Seruga et al.   Nature clinical practice. Oncology

Prolonged control of progressive castration-resistant metastatic prostate cancer with testosterone replacement therapy: the case for a prospective trial

(2007) P. Mathew   ANNALS OF ONCOLOGY